Compare J M Smucker Co (SJM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs 10X Genomics Inc — how do they compare? J M Smucker Co trades at $118.75 (market cap $12.54B), while 10X Genomics Inc trades at $56.8 (market cap $7.61B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.82% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SJM | TXG | |
|---|---|---|
Market Cap | $12.54B | $7.61B |
Sector | Consumer Staples | Health |
52-Week High | $126.35 | $58.57 |
52-Week Low | $89.53 | $11.34 |
Enterprise Value | $19.57B | $7.14B |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $118.79, up 0.61% today, with a bullish technical signal and analyst consensus price target of $125.11. Recent earnings have shown beats in Q4 2025 and Q1 2026, but the company reported a net loss of $1.23B in 2025, with negative profit margins and ROE. Cash flow from operations remains strong at $1.21B, supporting a dividend increase to $1.12 per share, marking 25 consecutive years of growth. The stock is supported by positive media coverage highlighting value and growth potential.
The outlook is mixed; strong cash flow and dividend growth provide stability, but profitability challenges and high debt levels pose risks. Analyst sentiment is predominantly buy-rated, suggesting upside potential, though investors must weigh fundamental weaknesses against technical and sentiment positives for balanced decision-making.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
